Daewon Pharmaceutical Croissance future

Future contrôle des critères 3/6

Daewon Pharmaceutical devrait augmenter ses bénéfices et son chiffre d'affaires de 45.6% et de 9.2% par an respectivement. Le BPA devrait croître de de 44.8% par an. Le rendement des capitaux propres devrait être 12.9% dans 3 ans.

Informations clés

45.6%

Taux de croissance des bénéfices

44.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	33.3%
Taux de croissance des recettes	9.2%
Rendement futur des capitaux propres	12.9%
Couverture par les analystes	Low
Dernière mise à jour	14 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Aug 13

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

Jul 17

There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Mar 21

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Mar 26

Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

Mar 07

Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

Feb 18

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Jan 31

Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

Jan 13

Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

Dec 24

Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Dec 10

Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

Nov 22

Prévisions de croissance des bénéfices et des revenus

KOSE:A003220 - Estimations futures des analystes et données financières antérieures (KRW Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	725,150	47,800	35,600	74,700	2
12/31/2025	670,700	43,400	31,900	68,900	2
12/31/2024	602,600	21,100	-52,500	58,000	1
9/30/2024	593,945	16,019	-23,103	23,974	N/A
6/30/2024	566,094	14,688	-27,439	3,232	N/A
3/31/2024	561,164	23,534	13,489	35,232	N/A
12/31/2023	526,952	23,917	31,124	51,734	N/A
9/30/2023	508,634	26,133	2,411	17,105	N/A
6/30/2023	501,899	31,749	18,273	30,359	N/A
3/31/2023	485,917	31,071	12,267	27,176	N/A
12/31/2022	478,885	31,944	13,048	26,413	N/A
9/30/2022	457,308	34,728	32,452	47,937	N/A
6/30/2022	425,588	29,928	29,070	43,137	N/A
3/31/2022	396,239	25,575	26,645	37,726	N/A
12/31/2021	354,176	6,989	10,707	22,413	N/A
9/30/2021	330,686	3,431	-1,072	9,864	N/A
6/30/2021	315,870	657	-2,219	10,266	N/A
3/31/2021	302,889	2,120	-5,196	9,803	N/A
12/31/2020	308,501	17,640	9,567	24,951	N/A
9/30/2020	318,297	24,073	17,186	32,837	N/A
6/30/2020	318,091	27,037	9,738	27,081	N/A
3/31/2020	322,124	28,904	3,497	25,727	N/A
12/31/2019	317,828	27,289	-5,681	30,971	N/A
9/30/2019	310,802	25,085	-11,697	37,498	N/A
6/30/2019	299,871	23,773	-14,584	38,140	N/A
3/31/2019	291,785	22,795	-16,335	32,324	N/A
12/31/2018	286,653	23,744	-2,550	40,032	N/A
9/30/2018	279,338	18,195	-9,540	24,814	N/A
6/30/2018	279,933	21,779	N/A	23,703	N/A
3/31/2018	273,784	14,212	N/A	22,066	N/A
12/31/2017	265,462	10,742	N/A	4,265	N/A
9/30/2017	258,275	14,662	N/A	14,033	N/A
6/30/2017	248,350	13,180	N/A	12,924	N/A
3/31/2017	245,490	19,632	N/A	21,123	N/A
12/31/2016	240,722	20,242	N/A	20,792	N/A
9/30/2016	235,046	20,787	N/A	19,544	N/A
6/30/2016	229,691	16,712	N/A	19,899	N/A
3/31/2016	222,267	17,791	N/A	19,164	N/A
12/31/2015	216,187	17,695	N/A	25,817	N/A
9/30/2015	208,270	17,453	N/A	25,040	N/A
6/30/2015	201,669	19,596	N/A	25,604	N/A
3/31/2015	190,870	17,286	N/A	21,799	N/A
12/31/2014	181,985	15,729	N/A	17,447	N/A
9/30/2014	174,309	14,143	N/A	12,782	N/A
6/30/2014	168,940	11,977	N/A	12,571	N/A
3/31/2014	165,717	12,625	N/A	15,754	N/A
12/31/2013	158,879	12,321	N/A	12,320	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de A003220 ( 45.6% par an) est supérieure au taux d'épargne ( 2.7% ).

Bénéfices vs marché: Les bénéfices de A003220 ( 45.6% par an) devraient croître plus rapidement que le marché KR ( 28% par an).

Croissance élevée des bénéfices: Les bénéfices de A003220 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de A003220 ( 9.2% par an) devrait croître plus lentement que le marché de KR ( 9.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de A003220 ( 9.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de A003220 devrait être faible dans 3 ans ( 12.9 %).

Daewon Pharmaceutical Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 7.6% to ₩21,250

Recent updates

New major risk - Financial data availability

Investor sentiment deteriorates as stock falls 15%

New major risk - Financial position

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

New minor risk - Shareholder dilution

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

Investor sentiment improves as stock rises 27%

There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%, EPS downgraded

Daewon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 22, 2024

Daewon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 22, 2024

Upcoming dividend of ₩350 per share at 2.2% yield

New minor risk - Profit margin trend

Now 21% undervalued

Price target decreased by 7.6% to ₩21,250

Upcoming dividend of ₩194 per share

No independent directors

Investor sentiment improved over the past week

No independent directors

Upcoming dividend of ₩152 per share

Daewon Pharmaceutical Co., Ltd. announced that it has received KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm

Daewon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS ₩894 (vs ₩1,368 in FY 2019)

Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

New 90-day low: ₩16,200

Daewon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021

Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

New 90-day low: ₩17,450

Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

Upcoming Dividend of ₩252 Per Share

Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

New 90-day low: ₩18,950

New 90-day high - ₩21,000

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance